Pyrrolo-[1, 2-a] imidazoles have been synthesized by diastereoselective of 1,3dipolar cycloaddition by using 4, 5-dihydroimidazolium ylides with an alkylating agent
and base or more recently carbenoid insertion to dihydroimidazoles.
For example, many alkylating agents
, such as cyclophosphamide and ifosfamide, are notorious for causing transient or permanent azoospermia.
Chlorambucil is an alkylating agent
with immunosuppressant and antineoplastic properties.
The compounds tested thus far include N-methyl-N'-nitro-nitrosoguanidine (an alkylating agent
similar to methyl methane sulfonate) and cadmium (a toxic metal found in tap water).
A patent -protected, potent cytotoxic drug and intraveneous formulation of the alkylating agent
Minnetonka, MN, worldwide rights to Busulfex Injection, an intravenous formulation of the alkylating agent
busulfan, a drug often used in bone marrow transplantation.
Ovarian damage may occur after high doses of abdominopelvic radiation and/ or alkylating agent
(cyclophosphamide, ifosfamide, mustard/procarbazine) chemotherapy are given.
b) A derivative [Hcy-acetylbenzoic acid (Hcy-ABA)] is formed by reacting with the alkylating agent
p-(2-chloroacetyl)benzoic acid phosphate (CABA-phosphate); and
Cisplatin is a heavy, metal alkylating agent
used in treating testicular, ovarian, Hodgkins and non-Hodgkins lymphomas, sarcomas, bladder, lung, esophagus, cervix and prostate cancers.
This particular alkylating agent
induces N7-methylguanine and N3-methyladenine at about 86% and 10% of total alkylation, respectively.
Apaziquone is an anticancer drug that requires activation by bio-reductive enzymes that are over-expressed in bladder cancer cells, to render it a cytotoxic alkylating agent
In summary, we presented a PMN patient refractory to alkylating agent
and CNI achieved complete remission with low-dose RTX, which suggests economical and effective treatment to PMN.
Each wafer contains carmustine, a nitrosourea alkylating agent
, distributed in a biodegradable polymer matrix.
Any regimen that has an alkylating agent
such as cyclophosphamide (Cytoxan), those patients are at high risk.
The reductive alkylating agent
design involves leaving group placement on the 4,g-dione (quinone) derivative of the title ring system so as to permit formation of an alkylating quinone methide species upon reduction to the hydroquinone and elimination of the leaving group.